Proposed US tariffs of 100-200% on imported generic medicines by 2029 could affect Indian pharmaceutical giants. Investors are evaluating the potential impact on revenue, profit margins, and the feasibility of shifting manufacturing to the United States.
Detailed Coverage
The United States has proposed a significant tariff policy targeting imported generic medicines. Under this plan, tariffs on these products could reach 100 percent initially, climbing to 200 percent by August 2029. The stated goal is to encourage pharmaceutical companies to move their manufacturing operations back to American soil. For the Indian pharmaceutical sector, which has long relied on the US as a primary export destination, this development introduces new layers of complexity regarding supply chain management and long-term profitability.
Indian pharmaceutical companies maintain a deep-rooted presence in the US market, with many firms generating between 20 percent and 64 percent of their total revenue from exports to the region. Major players such as Sun Pharma, Dr. Reddy’s Laboratories, Lupin, Cipla, Zydus Lifesciences, Biocon, Gland Pharma, and Syngene are currently evaluating the implications of these potential trade barriers. The challenge is not just about moving manufacturing but also about the economic viability of operating in the US, where labor and overhead costs are substantially higher than in India.
Building or expanding manufacturing facilities in the US requires heavy capital investment. Furthermore, even if companies decide to reshore, they would likely still depend on imported raw materials from India or China to produce these medicines, which would keep logistical and procurement costs elevated. For companies like Zydus Lifesciences, Biocon, Gland Pharma, and Syngene, where US revenue contributions are high, the potential for margin pressure is a critical area for investors to monitor.
The US generic drug market is already known for intense price competition, which often forces margins to thin out quickly after a product enters the market. Industry reports have noted that the US is already grappling with drug shortages, with product discontinuations rising by 60 percent in 2025. These shortages are often attributed to low profit margins that make the continued production of certain generic drugs unsustainable for manufacturers. Adding steep tariffs to this environment could potentially complicate the supply chain further, affecting the availability of essential medicines.
Investors may look toward future management commentary to understand how these companies plan to adjust their business models. Key factors to track include the status of existing US-based manufacturing infrastructure, potential changes in product mix to focus on higher-value specialty drugs, and any updates regarding regulatory or trade negotiations. The final impact on each company will depend on its current US footprint, its ability to manage production costs, and how the US government ultimately shapes these trade policies.